Factors associated with severe sepsis: Prospective study of 94 neutropenic febrile episodes

Hematology

Volumn 15, Issue 1, 2010, Pages 28-32

  Jeddi, Ramzi ^a   Achour, Mériem ^a   Amor, Ramzi Ben ^a   Aissaoui, Lamia ^a   Bouterĝa, Walid ^a   Kacem, Karima ^a   Lakhal, Raihane Ben ^a   Abid, Héla Ben ^a   Belhadjali, Zaher ^a   Turki, Amel ^a   Meddeb, Balkis ^a  

^a Hopital Aziza Othmana   (Tunisia)

Author keywords

Acute leukemia; Neutropenia; Sepsis

Indexed keywords

AMIKACIN; AMPHOTERICIN B; ANTINEOPLASTIC AGENT; C REACTIVE PROTEIN; CEFTAZIDIME; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; COLISTIN; GENTAMICIN; IMIPENEM; NORADRENALIN; OXACILLIN; PHOSPHATE; PIPERACILLIN PLUS TAZOBACTAM; PROTEIN; VANCOMYCIN;

ACINETOBACTER; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALCALIGENES; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BACTERIAL INFECTION; CHILD; COAGULASE NEGATIVE STAPHYLOCOCCUS; COLLOID; CONTINUOUS INFUSION; CONTROLLED STUDY; CRYSTALLOID; DISEASE ASSOCIATION; DISEASE SEVERITY; ESCHERICHIA COLI; FEBRILE NEUTROPENIA; FEMALE; FLUID THERAPY; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEART RATE; HUMAN; HYPOPHOSPHATEMIA; HYPOPROTEINEMIA; INTENSIVE CARE UNIT; KLEBSIELLA; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MICROBIOLOGICAL EXAMINATION; MYCOSIS; NEUTROPENIA; NEUTROPENIC ENTEROCOLITIS; PNEUMONIA; PREDICTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PSEUDOMONAS; SCHOOL CHILD; SEPSIS; SEPTIC SHOCK; SINUSITIS; SKIN INFECTION; STAPHYLOCOCCUS; STENOTROPHOMONAS; STREPTOCOCCUS; SYSTOLIC BLOOD PRESSURE;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; BACTEREMIA; BICARBONATES; BIOLOGICAL MARKERS; BLOOD PROTEINS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; FEVER OF UNKNOWN ORIGIN; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMODYNAMICS; HUMANS; HYPOPHOSPHATEMIA; IMMUNOCOMPROMISED HOST; LACTATES; MALE; MIDDLE AGED; NEUTROPENIA; POSTOPERATIVE COMPLICATIONS; RISK FACTORS; SEPSIS; SHOCK, SEPTIC; TUNISIA; YOUNG ADULT;

EID: 76849101648     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/102453310X12583347009577     Document Type: Article

References (29)

1. Klastersky J. Management of fever in neutropenic patients with different risks of complications. Clin Infect Dis 2004; 39: S32-S37.
2. Hughes WT, Pizzo PA, Wade JC, Armstrong D, Webb CD, Young LS. Evaluation of new anti-infective drugs for the treatment of febrile episodes in neutropenic patients. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis 1992; 15: 206-215.
3. Hughes WT, Armstrong D, Bodey GP et al. Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730-751.
4. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36: 296-327.
5. Carrigan SD, Scott G, Tabrizian M. Toward resolving the challenges of sepsis diagnosis. Clin Chem 2004; 1301-1314: 50-58.
6. American College of Chest Physician/Society of Critical Care Medicine Consensus Conference: definition for sepsis and organ failure guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20: 864-874.
7. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348: 1546-1554.
8. Angus DC, Linde-Zwirble WJ, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29: 1303-1310.
9. Sands KE, Bates DW, Lanken PN et al. Epidemiology of sepsis syndrome in 8 academic medical centers. JAMA 1997; 278: 234-240.
10. Rivers EP, McIntyre L, Morro DC, Rivers KK. Early and innovative interventions for severe sepsis and septic shock: taking advantage of a window of opportunity. CMAJ 2005; 173: 1054-1065.
11. Lin M, Weinstein RA, Hota B. Delay of active antimicrobial therapy and mortality among patients with bacteremia: impact of severe neutropenia. Antimicrob Agents Chemother 2008; 52: 3188-3194.
12. Chatzinikolaou I, Abi-Said D, Bodey GP, Rolston KV, Tarrand JJ, Samonis G. Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: retrospective analysis of 245 episodes. Arch Intern Med 2000; 160: 501-509.
13. Maschmeyer G, Braveny I. Review of the incidence and prognosis of Pseudomonas aeuriginosa infection in cancer patients in the 1990s. Eur J Clin Microbiol Infect Dis 2000; 19: 915-925.
14. Pizzo PA, Armstrong D, Bodey G, de Pauw B, Feld R, Glauser M. From the Immunocompromised Host Society. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. Report of a consensus panel. J Infect Dis 1990; 161: 397-401.
15. Russell JA. Management of sepsis. N Engl J Med 2006; 355: 1699-1713.
16. Penack O, Beinert T, Buchheidt D et al. Management of sepsis in neutropenia: guidelines of the infectious diseases working party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2006; 85: 424-433.
17. Rivers E, Ngyuyen B, Havstad S et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345: 1368-1377.
18. Baxter F. Septic shock. Can J Anaesth 1997; 44: 59-72.
19. Ramzi J, Mohamed Z, Yosr B et al. Predictive factors of septic shock and mortality in neutropenic patients. Hematology 2007; 12: 543-548.
20. Brunelli SM, Goldfarb S. Hypophosphatemia: clinical consequences and management. J Am Soc Nephrol 2007; 18: 1999-2003.
21. Wilkes P. Hypoproteinemia, strong ion difference, and acid-base status in critically ill patients. J Appl Physiol 1998; 84: 1740-1748.
22. Margarson MP, Soni NC. Effects of albumin supplementation on microvascular permeability in septic patients. J Appl Physiol 2001; 92: 2139-2145.
23. Kumar A, Roberts D, Wood KE et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34: 1589-1596.
24. Lefer AM, Martin J. Origin of the myocardial depressant factor in shock. Am J Physiol 1970; 218: 1423-1429.
25. Parrillo JE, Burch C, Shelhamer JH, Parker MM, Natanson C, Schuette W. A circulating myocardial depressant substance in humans with septic shock. J Clin Invest 1985; 76: 1539-1553.
26. Price S, Anning PB, Mitchell JA, Evans TW. Myocardial dysfunction in sepsis: mechanisms and therapeutic implications. Eur Heart J 1999; 20: 715-724.
27. Merx MW, Weber C. Sepsis and the heart. Circulation 2007; 116: 793-802.
28. Alberti C, Brun-Buisson C, Chevret S et al. For the European Sepsis Study Group. Am J Respir Crit Care Med 2005; 171: 461-468.
29. Santolaya ME, Alvarez AM, Becker A et al. Prospective, multicenter evaluation of risk factors associated with invasive bacterial infection in children with cancer, neutropenia and fever. J Clin Oncol 2001; 19: 3415-3421.